Youtor
Proton Pump Inhibitors PPIS
>> YOUR LINK HERE: ___ http://youtube.com/watch?v=wxudIfY03Gg
Pharmacology 2 assessment. • Group includes: • 1. Huda Amailef 11709007 • 2. Monika Gibryal 11454396 • 3. Carly Italiano 11702913 • 4. Mona El-Mohtadi 11417464 • References: • 1.Bratanic, A., Kokic, S., Hozo, I., Barisic, I. and Kokic, V. (2009). Long-term therapy with proton pump inhibitors is associated with decreased bone density. Medical Hypotheses, 72(5), pp.608-609. • 2. Chapman, D., Rees, C., Lippert, D., Sataloff, R. and Wright, S. (2011). Adverse Effects of Long-Term Proton Pump Inhibitor Use: A Review for the Otolaryngologist. Journal of Voice, 25(2), pp.236-240. • 3. fda.gov, (2011). FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. [online] Available at: http://www.fda.gov/Drugs/DrugSafety/P... [Accessed 1 Sep. 2015]. • 4. Fournier, M., Targownik, L. and Leslie, W. (2009). Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures. Maturitas, 64(1), pp.9-13. • 5. Heidelbaugh, J., Metz, D. and Yang, Y. (2012). Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk?. International Journal of Clinical Practice, 66(6), pp.582-591. • 6.Laine, Ahnen, Mcclain, Solcia, and Walsh, (2000). Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Alimentary Pharmacology and Therapeutics, 14(6), pp.651-668. • 7. Lau, A., Tomizza, M., Wong-Pack, M., Papaioannou, A. and Adachi, J. (2015). The relationship between long-term proton pump inhibitor therapy and skeletal frailty. Endocrine, 49(3), pp.606-610. • 8. Lodato, F., Azzaroli, F., Turco, L., Mazzella, N., Buonfiglioli, F., Zoli, M. and Mazzella, G. (2010). Adverse effects of proton pump inhibitors. Best Practice Research Clinical Gastroenterology, 24(2), pp.193-201. • • 9.Naunton, M., Peterson, G. and Bleasel, M. (2000). Overuse of proton pump inhibitors. Journal of Clinical Pharmacy and Therapeutics, 25(5), pp.333-340. • 10.Ogielska, M., Lanotte, P., Le Brun, C., Valentin, A., Garot, D., Tellier, A., Halimi, J., Colombat, P., Guilleminault, L., Lioger, B., Vegas, H., De Toffol, B., Constans, T. and Bernard, L. (2015). Emergence of community-acquired Clostridium difficile infection: the experience of a French hospital and review of the literature. International Journal of Infectious Diseases, 37, pp.36-41. • 11.Pbs.gov.au, (2015). Pharmaceutical Benefits Scheme (PBS) | Australian Statistics on Medicines 2014. [online] Available at: http://pbs.gov.au/info/statistics/asm... [Accessed 1 Sep. 2015]. • 12.Raghunath, A., O'Morain, C. and McLoughlin, R. (2005). Review article: the long-term use of proton-pump inhibitors. Alimentary Pharmacology and Therapeutics, 22(s1), pp.55-63. • 13. Reyes, C., Formiga, F., Coderch, M., Hoyo, J., Ferriz, G., Casanovas, J., MonteserÃn, R., Brotons, C., Rojas, M. and Moral, I. (2013). Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region. Bone, 52(2), pp.557-561. • 14. Richardson, P., Hawkey, C. and Stack, W. (1998). Proton Pump Inhibitors. Drugs, 56(3), pp.307-335. • 15.Sarkar, M. (2008). Proton-Pump Inhibitor Use and the Risk for Community-Acquired Pneumonia. Annals of Internal Medicine, 149(6), p.391. • 16. Sheen, E. and Triadafilopoulos, G. (2011). Adverse Effects of Long-Term Proton Pump Inhibitor Therapy. Dig Dis Sci, 56(4), pp.931-950.
#############################
